Gapping up
Select metals/mining stocks trading higher: VALE +1.7%, BHP +1.4%, BBL +1%, SLV +0.7%
A few oil/gas related names showing strength following Libya oil storage tank fire: SDRL +2.8%, RIG +1.6%, BP +0.3%, BRGYY +0.5% ( loads first LNG cargo from QCLNG project in Australia) .
Select biotech/pharma names are trading higher boosted by GILD upgrade: GILD +1.9% (upgraded to Overweight from Equal Weight at Morgan Stanley), ISIS +2.0%, ACHN +1.6%, ARRY +1.1%.
Other news: NAK +14% (thinly traded; expects to privately place with investors and management ~36 mln Special Warrants priced at C$0.431 per Special Warrant to raise ~C$15.5 mln), MTW +12.3% ( Carl Icahn discloses 7.7% stake in 13D; intend to have discussions relating to separating Crane and Foodservice segments ), JUNO +4.7% (Juno disclosed license agreement conditions with Opus Bio were satisfied; paid Opus Bio $20.0 mln in cash and issued to Opus Bio 1,602,564 shares of common stock of the Company), VJET +3.1% (continued strength), GSK +0.9% (still checking), ARRS +0.9% (light volume; Barron's profiles positive view on Arris)
Analyst comments: BLUE +2.2% (ticking higher; A potential cure for SCD may not be far fetched; target raised to $120 from $90, maintain Buy at ROTH Capital)
A few oil/gas related names showing strength following Libya oil storage tank fire: SDRL +2.8%, RIG +1.6%, BP +0.3%, BRGYY +0.5% ( loads first LNG cargo from QCLNG project in Australia) .
Select biotech/pharma names are trading higher boosted by GILD upgrade: GILD +1.9% (upgraded to Overweight from Equal Weight at Morgan Stanley), ISIS +2.0%, ACHN +1.6%, ARRY +1.1%.
Other news: NAK +14% (thinly traded; expects to privately place with investors and management ~36 mln Special Warrants priced at C$0.431 per Special Warrant to raise ~C$15.5 mln), MTW +12.3% ( Carl Icahn discloses 7.7% stake in 13D; intend to have discussions relating to separating Crane and Foodservice segments ), JUNO +4.7% (Juno disclosed license agreement conditions with Opus Bio were satisfied; paid Opus Bio $20.0 mln in cash and issued to Opus Bio 1,602,564 shares of common stock of the Company), VJET +3.1% (continued strength), GSK +0.9% (still checking), ARRS +0.9% (light volume; Barron's profiles positive view on Arris)
Analyst comments: BLUE +2.2% (ticking higher; A potential cure for SCD may not be far fetched; target raised to $120 from $90, maintain Buy at ROTH Capital)